Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Kexing Biopharm Co., Ltd. is a biotechnology firm based in China, specializing in the development and manufacturing of vaccines and biologics. The company has a competitive edge through its proprietary vaccine technologies and strong partnerships with local health authorities, which drive its revenue growth in the rapidly expanding Chinese healthcare market.
Kexing generates revenue primarily through the sale of vaccines, leveraging its proprietary technologies to maintain pricing power and secure contracts with government health agencies. The company benefits from economies of scale in production, allowing it to maintain high gross margins.
Approval and launch of new vaccines, particularly in the COVID-19 and influenza markets
Partnerships with government health organizations for vaccine distribution
Changes in regulatory policies affecting vaccine production and pricing
Market demand for vaccines in emerging markets
Regulatory changes impacting vaccine approval processes
Technological disruption from new vaccine development methods
Increased competition from both domestic and international biotech firms
Potential for price wars in the vaccine market
Moderate debt levels could constrain future growth if not managed properly
Liquidity risks if cash flow does not improve significantly
moderate - The demand for vaccines is somewhat insulated from economic cycles, but overall healthcare spending can be influenced by GDP growth.
Kexing's financing costs may increase with rising interest rates, impacting its ability to fund R&D and expansion projects, although the direct impact on demand for vaccines is limited.
minimal - The company has a manageable debt-to-equity ratio of 0.82, indicating limited reliance on external financing.
growth - Investors are likely attracted to Kexing due to its potential for high revenue growth driven by vaccine demand.
high - The stock has shown significant volatility, with a 1-year return of -65.5%, indicating a high-risk profile.